Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Advanced ER+ Breast Cancer
NCT03332797Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Nov 2017
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of Belvarafenib in breast cancer (12 arms), sponsored by Genentech. Primary endpoints: Number of Participants with Adverse Events by Severity up to 84 months, Maximum Tolerated Dose or Maximum Administered Dose and 15 more. Started Nov 2017; status: active, not recruiting.
02
Drugs
Belvarafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03332797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03332797.